Tissue derived porous matrices for treating wounds are provided, as well as methods for making and using them. The tissue derived porous matrices comprise processed tissue of any of several types, such as dermis, adipose, etc., and have a plurality of interconnected pores which allow fluid flow through the matrices. The tissue derived matrices are biocompatible resorbable matrices which remodel with native tissue and facilitate and enhance cell infiltration and tissue ingrowth into the matrices during the wound healing process, thereby enhancing wound healing and tissue remodeling when implanted into a patient. The tissue derived matrices are useful with reduced or negative pressure wound healing methods and systems, without the need to repeatedly revisit the treatment site and remove previously implanted matrices.

Disclosed are compositions derived from non-primate mammals having reduced expression of alpha 1,3 gal and their use in food products, food additives, cosmetic products, cosmetic additives, medical products, medical devices and products used in research and production of therapeutics. The compositions and methods disclosed are particularly useful to subjects diagnosed with α-Gal Syndrome (AGS).

Tissue-regenerating wound treatments, methods of producing tissue-regenerating wound treatments, and methods of treating a wound using a tissue-regenerating wound treatment are provided. The tissue-regenerating wound treatment includes a skin substitute and a coloring agent added to the skin substitute. The coloring agent is a biocompatible coloring agent that degrades upon protease attack within a treated wound.

The invention relates to crosslinked soft tissue grafts and methods of use thereof. The invention also relates to methods of preparing the same.

The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes.

The present disclosure relates to tissue matrix products. The products can includes tissue matrices that have holes or perforations located at certain positions to improve certain in vivo functions without substantial loss of strength or other important properties.

Provided is a method of manufacturing a bone grafting substitute having a hole. The method of manufacturing a bone grafting substitute having a hole includes a biodegradable polymer preparation operation of preparing biodegradable polymer; a molding material preparation operation of preparing a molding material by mixing the biodegradable polymer with a bone material; a molding material injection operation of injecting the molding material into a hole forming mold for molding a bone grafting substitute having a hole; and a bone grafting substitute having a hole molding operation of drying the molding material injected into the hole forming mold at a predetermined temperature.

The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue.

The present disclosure relates to methods for producing tissue matrix products with active agents to achieve localized distribution and controlled active agent release. The method can include inserting a carrier element comprising a biodegradable material and active agent into surface features of a tissue matrix product. Also provided are tissue matrix products made using the disclosed methods.

The method for tin vitro or ex vivo amplification of human adipose tissue stem cells includes: —extracting a stromal vascular fraction of a human adipose tissue including endothelial cells of the human adipose tissue vascular network and human adipose tissue stem cells, and an extracellular matrix of the human adipose tissue, the extracellular matrix including endothelial cells of the human adipose tissue vascular network, human adipose tissue stem cells and collagen; —mixing the stromal vascular fraction and the extracellular matrix; and—culturing the mixture obtained in the preceding step, in suspension, in a culture medium.